Review paper
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A
Abstract
Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is the development of neutralizing alloantibodies, known as FVIII inhibitors. HA patients who develop FVIII inhibitors have limited treatment options available to them and experience greater disease- and treatment-related burdens than HA patients without FVIII...
Paper Details
Title
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A
Published Date
Jun 16, 2019
Journal
Volume
119
Issue
09
Pages
1384 - 1393
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History